| Company: | Arrowhead Research Corp. |
| Ticker Symbol: | ARWR |
| Class Period: | Aug-12-14 to Oct-8-14 |
| Date Filed: | Oct-10-14 |
| Lead Plaintiff Deadline: | Dec-9-14 |
| Court: | Central District of California |
| Allegations: | |
The complaint alleges that Arrowhead Research materially misstated clinical trial information from its experimental hepatitis B therapy ARC-520 by falsely suggesting that the therapy was more effective than it actually was.
On October 8, 2014, Arrowhead Research released disappointing data for its experimental therapy. That same day, it was reported on TheStreet.com that the Company had misled investors as to the potency and achieved viral load reductions of the therapy. Upon this news shares of Arrowhead Research fell over 43% to close at $7.03 per share on October 8, 2014.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
